Tax
Tax Reconciliation at Federal Statutory Rate
Vertex Pharmaceuticals Tax Reconciliation at Federal Statutory Rate remained flat by 0.0% to $0.05 in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $0.05 to $0.05. Over 2 years (FY 2023 to FY 2025), Tax Reconciliation at Federal Statutory Rate shows relatively stable performance with a 0.0% CAGR.
Analysis
StatementIncome Statement
SectionTax
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
Metric ID:
isrg_tax_reconciliation_at_federal_statutory_rateHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $0.21 | $0.21 | $0.21 |
| YoY Change | — | +0.0% | +0.0% |
Range$0.21 – $0.21
CAGR+0.0%
Avg YoY Growth+0.0%
Median YoY Growth+0.0%
Current Streak2+ years growth
Tax Reconciliation at Federal Statutory Rate at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's tax reconciliation at federal statutory rate?
- Vertex Pharmaceuticals (VRTX) reported tax reconciliation at federal statutory rate of $0.05 in Q4 2025.
- How has Vertex Pharmaceuticals's tax reconciliation at federal statutory rate changed year-over-year?
- Vertex Pharmaceuticals's tax reconciliation at federal statutory rate decreased by 0.0% year-over-year, from $0.05 to $0.05.
- What is the long-term trend for Vertex Pharmaceuticals's tax reconciliation at federal statutory rate?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's tax reconciliation at federal statutory rate has grown at a 0.0% compound annual growth rate (CAGR), from $0.21 to $0.21.